Phase 2 N=29 Memantine Treatment Study of Pathological Gambling
Pathological Gambling
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) — 21.8; 8.9 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
Metabolic Diseases · Hyperlipidemias · Metabolic Disorder
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point — -2.0; -47.3 percentage of baseline — p=<0.001
Phase 2 N=21 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Lipid Metabolism, Inborn Errors · Hypercholesterolemia, Autosomal Dominant · Hyperlipidemias
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -16.2; -2.6; -32.4; 30.6 percentage of baseline
Phase 2 N=47 Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Number of Participants With Complete Response — 39 participants
Phase 2 N=79 Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
Hepatitis C
Primary: Patients Who Are Negative for Hepatitis C Virus (HCV) RNA at 3 Months Post-transplant: Intent-to-Treat Analysis (ITT) — 0; 5; 6 participants — p=0.0477
Phase 2 N=50 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
Recurrent Prostate Carcinoma · Stage I Prostate Cancer · Stage IIA Prostate Cancer
Primary: Proportion of Patients Free of PSA Progression at 6 Months (Prior to the Start of Androgen Ablation) — 0.625 Proportion of patients
Phase 2 N=22 A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
NSCLC · Solid Tumors
Primary: Phase 1 Safe and Tolerable Phase 2 Dose. — 10 mg/m^2
Phase 2 N=19 Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents
Adolescent Methamphetamine Abuse
Primary: Feasibility of Retaining Adolescents in Trial — 33.3; 49.3 days — p=0.08
Phase 2 N=32 Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Glioblastoma · Gliosarcoma
Primary: 6-month Progression-free Survival (PFS) — 3.1 percentage of participants
Phase 2 N=92 Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
Chronic Ischemic Heart Disease · Left Ventricular Dysfunction · Angina
Primary: Change in Maximal Oxygen Consumption (VO2max) — -0.6; 0.4 mL/kg/min — p=0.169
Phase 2 N=41 Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Prostate Cancer
Primary: Protein-specific Antigen (PSA) Response Rate — 3 percentage of patients
Phase 2 N=120 Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)
Left Ventricular Dysfunction
Primary: Global Left Ventricular Function — 3.5; 4.4; 2.8; 1.7 percentage of ejection fraction — p=0.959
Phase 2 N=41 Lamivudine and Adefovir to Treat Chronic Hepatitis B
HBV (Hepatitis B Virus) · Hepatitis B · Hepatitis
Primary: Maintained Combined Response (Virological, Biochemical and Histological Response). — 15; 6; 7; 13 participants — p=0.0294
Phase 2 N=112 A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Assessed by the Independent Review Facility Using Response Evaluation Criteria in Solid Tumors (RECIST) — 25.7; 26.9 Percentage of patients
Phase 2 N=204 Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Stage III Squamous Cell Carcinoma of the Hypopharynx · Stage III Squamous Cell Carcinoma of the Larynx · Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Comparison of the Percentage of Participants With a Complete Response in Each Treatment Arm — 42; 51 percentage of participants